Use of Non-GAAP Measures Page 3 PolyOne Commodity to Specialty Transformation • Volume driven, commodity producer • Heavily tied to cyclical end markets • Performance largely dependent on non- controlling joint ventures 2000-2005 2006 - 2009 2010 – 2014 2015 and beyond • Steve Newlin appointed, Chairman, President and CEO • New leadership team appointed • Implementation of four pillar strategy • Focus on value based selling, investment in commercial resources and innovation to drive transformation • 18 consecutive quarters of double- digit adjusted EPS growth • Shift to faster growing, high margin, less cyclical end markets • Key acquisitions propel current and future growth, as well as margin expansion • Established aggressive 2015 targets • Continue specialty transformation • Targeting $2.50 Adjusted EPS by 2015, nearly double 2013 EPS • Drive double digit operating income and adjusted EPS growth Confirmation of Our Strategy The World’s Premier Provider of Specialized Polymer Materials, Services and Solutions Specialization Globalization Operational Excellence Commercial Excellence -150.00% -50.00% 50.00% 150.00% 250.00% 350.00% 450.00% PolyOne S&P 500 Russell 2000 Dow Jones Chemical All time high of $39.28 April 4th, 2014 • 18 consecutive quarters of double digit EPS growth • 49% CAGR adjusted EPS expansion 2006-2013 • 2013 stock price increased 73% versus 30% growth in the S&P • More than seven fold increase in market cap: $0.5b $3.6b Strategy and Execution Drive Results Page 6 Appliance 4% Building & Construction 13% Wire & Cable 9% Electrical & Electronics 5% Consumer 10%Packaging 16% Industrial 12% HealthCare 11% Transportation 18% Misc. 2% 0.12 0.27 0.21 0.13 0.68 0.82 1.00 1.31 2.50 $0.00 $0.25 $0.50 $0.75 $1.00 $1.25 $1.50 $1.75 $2.00 $2.25 $2.50 2006 2007 2008 2009 2010 2011 2012 2013 2015 Target Ad ju st ed E ar ni ng s P er S ha re 2013 Revenues: $3.8 Billion End Markets 2013 Revenues: $3.8 Billion EPS Page 7 PolyOne At A Glance United States 67% Europe 14% Canada 7% Asia 6% Latin America 6% Specialty 54% PP&S 18% Distribution 28% Mix Shift Highlights Specialty Transformation Page 8 Old PolyOne Transformation *Operating Income excludes corporate charges and special items 2% 34% 43% 62% 64% 0% 20% 40% 80% 2005 2008 2010 2013 Q1 2014 2015 % o f O pe ra tin g In co m e* JV's Performance Products & Solutions Distribution Specialty 65-75% Specialty OI $5M $46M $87M $195M $60M Target 2015 Target Proof of Performance & 2015 Goals Page 9 2006 Q1 2014 2015 “Where we were” “Where we are” Target 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 13.8% 12 – 16% Global Specialty Engineered Materials 1.1% 11.6% 12 – 16% Designed Structures & Solutions -- 6.5% 8 – 10% Performance Products & Solutions 5.5% 7.7% 9 – 12% Distribution 2.6% 6.1% 6 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 64% 65 – 75% 3) ROIC* (after-tax) 5.0% 9.4% 15% 4) Adjusted EPS Growth N/A 42% Double Digit Expansion *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Bridge to $2.50 Adjusted EPS by 2015 2015 EPS: $2.50 2013 EPS: $1.31 Continued Gross Margin Expansion Mergers & Acquisitions Spartech Accretion Incremental share buybacks Ongoing LSS Programs (50-100 bps/yr) Accelerated Innovation & Mix Improvement Several Levers to Drive Growth Mid single digit revenue CAGR Innovation Drives Earnings Growth $20.3 $52.3 2006 2013 Research & Development Spending ($ millions) Specialty Platform Vitality Index Progression* *Percentage of Specialty Platform revenue from products introduced in last five years Page 11 14.3% 30.7% 2006 2013 Specialty Platform Gross Margin % 19.5% 42.0% 2006 Q1 2014 Healthcare Consumer Packaging and Additive Technology Transportation Page 12 Unique and Innovative Solutions https://www.dropbox.com/sh/dwe4t8aacvhb8ui/uD3p_bdglP/Presentation revise pics/GLS Beverage can closure XO 2.jpg https://www.dropbox.com/sh/dwe4t8aacvhb8ui/-YgkycKypw/Anti-Counterfeiting release & images/GN1979.JPG 60% 100% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2008 2014 Pension Funding** As of March 31, 2014 Debt Maturities & Pension Funding – 3/31/14 Net Debt / EBITDA* = 1.9x $48 $317 $600 $0 $100 $200 $300 $400 $500 $600 $700 $800 2015 2020 2023 Debt Maturities As of March 31, 2014 ($ millions) Coupon Rates: 7.500% 7.375% 5.250% ** includes US-qualified pension plans only *TTM 3/31/2014 Free Cash Flow and Strong Balance Sheet Fund Investment / Shareholder Return $0.16 $0.20 $0.24 $0.32 $0.10 $0.20 $0.30 $0.40 2011 2012 2013 2014 Annual Dividend  Expanding our sales, marketing, and technical capabilities  Investing in operational and initiatives that drive profitability growth Manufacturing realignment  Targets that expand our: • Specialty offerings • End market presence • Geographic footprint • Operating Margin  Synergy opportunities  Adjacent material solutions  Repurchased 1.4 million shares in Q1 2014  Repurchased 6.4 million shares since April 2013  13.6 million shares are available for repurchase under the current authorization Organic Growth Acquisitions Share Repurchases Dividends The New PolyOne: A Specialty Growth Company Why Invest In PolyOne? ���PolyOne Investor Presentation�5th Annual Wells Fargo�Industrial and Construction Conference �May 8, 2014 �� Forward – Looking Statements Use of Non-GAAP Measures PolyOne Commodity to Specialty Transformation Confirmation of Our Strategy Strategy and Execution Drive Results PolyOne�At A Glance Mix Shift Highlights Specialty Transformation Proof of Performance & 2015 Goals Bridge to $2.50 Adjusted EPS by 2015 Innovation Drives Earnings Growth Unique and Innovative Solutions Debt Maturities & Pension Funding – 3/31/14 Free Cash Flow and Strong Balance Sheet �Fund Investment / Shareholder Return Why Invest In PolyOne?

S&P 500 -150% -50% 50% 150% 250% 350% 450% 550% POL S&P 500 All time high of $43.34 July 1st, 2014 PolyOne Corporation Page 9 2006 2014 YTD 2015 “Where we were” “Where we are” Target 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 14.9% 12 – 16% Global Specialty Engineered Materials 1.1% 12.1% 12 – 16% Designed Structures & Solutions -- 7.6% 8 – 10% Performance Products & Solutions 5.5% 8.1% 9 – 12% Distribution 2.6% 6.2% 6 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 65% 65 – 75% 3) ROIC* 5.0% 10.6% 15% 4) Adjusted EPS Growth N/A 37% Double Digit Expansion Proof of Performance & 2015 Goals *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period PolyOne Corporation Page 10 32% Adjusted EPS CAGR from 2011 2015 EPS: $2.50 2011 EPS: $0.82 Continued Gross Margin Expansion Mergers & Acquisitions Spartech Accretion Incremental Share Buybacks Ongoing LSS Programs (50-100 bps/yr) Accelerated Innovation & Mix Improvement Several Levers to Drive Growth Mid Single Digit Revenue Growth PolyOne Corporation Page 11 Innovation Drives Earnings Growth *Percentage of Specialty Platform revenue from products introduced in last five years $20 $53 2006 2013 Research & Development Spending ($ millions) Specialty Platform Vitality Index Progression* 14% 31% 2006 2013 Specialty Platform Gross Margin % 20% 43% 2006 2013 Specialty Vitality Index Target ≥ 35% Vitality Products + 700 to 1000 bps PolyOne Corporation Page 12 Prototype Frame Opportunity Scale-up & Test Market Build Business Case Commercial Launch Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 4 11 5 10 6 9 3 4 2 15 9 1 10 4 Breakthrough Platform Derivative A Rich Pipeline of Opportunity Number of Projects 25 14 19 17 18 93 Addressable Market ($ millions) TBD TBD $800 $450 $450 $1,700 PolyOne Corporation Page 13 Megatrends Aligned with Key End Markets Decreasing Dependence on Fossil Fuels Protecting the Environment Improving Health and Wellness Megatrend End Markets Globalizing and Localizing Health & Wellness Transportation Packaging Consumer PolyOne Corporation Page 14 60% 100% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2008 2014 Pension Funding** As of September 30, 2014 Debt Maturities & Pension Funding – 9/30/14 Net Debt / EBITDA* = 1.7x $48 $317 $600 $0 $100 $200 $300 $400 $500 $600 $700 $800 2015 2020 2023 Debt Maturities As of September 30, 2014 ($ millions) Coupon Rates: 7.500% 7.375% 5.250% ** includes US-qualified pension plans only *TTM 9/30/2014 PolyOne Corporation Page 15 Free Cash Flow and Strong Balance Sheet Fund Investment / Shareholder Return Expanding our sales, marketing, and technical capabilities Targets that expand our: • Specialty offerings • End market presence • Geographic footprint • Operating Margin Synergy opportunities Adjacent material solutions Repurchased 1.5 million shares in Q3 2014 Repurchased 9.7 million shares since early 2013  10.3 million shares are available for repurchase under the current authorization Organic Growth Acquisitions Share Repurchases Dividends  Investing in operational and LSS initiatives (including synergy capture) Manufacturing alignment $0.16 $0.20 $0.24 $0.32 $0.40 $0.10 $0.20 $0.30 $0.40 $0.50 2011 2012 2013 2014 2015 Annual Dividend PolyOne Corporation Page 16 PolyOne Core Values Innovation Collaboration Excellence PolyOne Corporation Page 17 The New PolyOne: A Specialty Growth Company Why Invest In PolyOne? ��PolyOne Investor Presentation�Goldman Sachs 2014 US Emerging / SMID Cap Growth Conference�New York, NY�November 20, 2014�� Forward-Looking Statements Use of Non-GAAP Measures PolyOne Commodity to Specialty Transformation PolyOne�At A Glance Mix Shift Highlights Specialty Transformation Confirmation of Our Strategy Strategy and Execution Drive Results Proof of Performance & 2015 Goals 32% Adjusted EPS CAGR from 2011 Innovation Drives Earnings Growth A Rich Pipeline of Opportunity Megatrends Aligned with Key End Markets Debt Maturities & Pension Funding – 9/30/14 Free Cash Flow and Strong Balance Sheet �Fund Investment / Shareholder Return PolyOne Core Values Why Invest In PolyOne?

Leadership, EHS&S-PS, Facility Services, Design & Development, Information Technology, Sourcing, Logistics, Legal, and Human Resources 33587 Walker Road Avon Lake OH 44012 United States Kornkamp 50 Ahrensburg Schleswig- Holstein 22926 Germany Avient Corporation - Albany Design and Manufacture of Colorants and Additives for Plastics 4 Rothwell Ave, PO Box 300-009 Auckland 0632 New Zealand Avon Lake Color Design and Manufacture of Specialty Engineered Thermoplastics 33587 Walker Road, Building 416 Avon Lake OH 44012 United States Avient Corporation Design and Manufacture of Specialty Engineered Thermoplastics Pol. Water Street North Baltimore OH 45872 United States NEU Specialty Engineered Materials, LLC Compound, Supply, and Prototyping Services of Thermoplastics 15 Corporate Drive North Haven CT 06473 United States Avient Corporation Design and Manufacture of Colorants and Additives for Plastics 80 North West Street Norwalk OH 44857 United States Page 3 of 5 Avient Corporation Manufacture of Masterbatches, Additives, ECCOH, and Compounds for Pigmenting Thermoplastic Pol. Ezcabarte calle H Nº3 , 31194 Oricain, Spain Avient Corporation Design and Manufacture of Colorants and Additives for Plastics 700/848 Moo 1,Tambol Phan Thong, Amata City Chonburi Industrial Estate Phan Thong Chonburi 20160, Thailand Avient Corporation Manufacture of Colour and Additive Concentrates, Thermoplastic Resins and Specialty Compounds Via Lainate 26, 20005 Pogliano Milanese, Italy Avient Corporation Manufacture of Masterbatches 329 Tungsten Rd, Strydompark , 2194 Randburg, South Africa PolyOne Polymers India Private Limited Design & Manufacture of Color, Additive Concentrate & Specialty Survey No.344/1-2-3, Rania Works, Sakarda Bhadarwa Road Rania Gujarat 391780 India Avient Corporation Design and Manufacture of Color and Additive Concentrates, Thermoplastic Resins and Specialty Compounds 2nd Industrial City, Al-Kharj Road , 11432 Riyadh, Saudi Arabia Crta.

DEVICE MANUFACTURER M E D I C A L D E V I C E H O U S I N G • Improved chemical resistance compared to PC/ABS, PC/PET & COPE • Flame retardant (FR) rating of V-1 at 0.75 mm • Zero BPA & non-halogenated FR material • Available in standard hospital grade pre-colors • Provided a cost-effective material with superior chemical resistance to traditional materials • Formulated a medical-grade, semi-crystalline blend to support regulatory testing and approvals • Demonstrated superior property retention and crack resistance after exposure to hospital- grade disinfectants, including Virex® Tb, helping to extend the device life Trilliant™ HC8900 Thermoplastics KEY REQUIREMENTS WHY AVIENT? https://www.avient.com/products/engineered-polymer-formulations/chemical-corrosion-resistant-formulations/trilliant-hc-healthcare-thermoplastics

Trilliant HC - OCD Microwells IVD Testing - Application Snapshot ORTHO CLINICAL DIAGNOSTICS M I C R O W E L L S F O R I V D D E V I C E • PS-based material • Strict TiO2 content/filling to secure accurate performance • Material to be suitable and complaint with the IVDD/IVDR standards • Surface chemical performance essential for the application • Worked in close collaboration with customer and internal teams to fully understand and overcome current material challenges • Identified anomalies in existing formulation using material science expertise and customized an alternative formulation • Enabled customer to improve processing efficiency, reduce scrap rate and respond to the increased market demand Trilliant™ HC7410-5001 X4 thermoplastics in white KEY REQUIREMENTS WHY AVIENT? https://www.avient.com/products/engineered-polymer-formulations/chemical-corrosion-resistant-formulations/trilliant-hc-healthcare-thermoplastics

https://www.avient.com/products/thermoplastic-elastomers/versaflex-thermoplastic-elastomers

https://www.avient.com/products/thermoplastic-elastomers/versaflex-thermoplastic-elastomers

https://www.avient.com/products/thermoplastic-elastomers/onflex-thermoplastic-elastomers

PROCESS OVERVIEW Polystrand™ advanced thermoplastic composites combine high strength, unidirectional, continuous fibers with engineered thermoplastic resins to create continuous fiber reinforced thermoplastic (CFRTP) materials that feature exceptional strength-to-weight ratio and high impact resistance. Overmolding integrates Polystrand tapes and multi- ply laminates into traditional thermoplastic molding processes, such as injection and compression molding, to create locally-reinforced, molded components. Overmolding with Polystrand™ Continuous Fiber Reinforced Thermoplastic Composites Processability Meets Performance Overmolding with Polystrand CFRTP can enhance the performance of traditional thermoplastics or enable metal replacement in a wide range of applications.

Thermoplastic Composite Innovation Cell Injection and Compression Overmolding HARNESS THE VERSATILITY Are you working on a project that would benefit from added reinforcement, reduced weight, material reduction or part consolidation? CAPABILITIES • Prototype part sampling • Tooling validation • Process optimization • Material configuration • Application development support • Laminate analysis • Mechanical system analysis • Resin flow with laminate inserts • Finite Element Analysis EQUIPMENT SPECIFICATIONS Injection Molding • Milacron-Fanuc Roboshot α-S15OiA with 4-axis robot • Maximum shot capability at 171 grams with a clamping for 198 tons • Trial molds include a 4"x6" flat plaque and a 3"x10" hat stiffening member Compression Molding • 450 ton down acting press • 39" x 39" platen size • Features automatic shuttle table with IR preheat oven Material Testing • Instron Model 5982 Universal Testing System with 100 kN load capacity • AVE2 non-contacting video extensometer with digital image correlation capability • Environmental chamber that enables testing from -150° to 350° C PRODUCT BULLETIN PROCESSABILITY MEETS PERFORMANCE Polystrand™ advanced thermoplastic composites combine high strength, unidirectional, continuous fibers with engineered thermoplastic resins to create continuous fiber reinforced thermoplastic (CFRTP) materials that feature exceptional strength-to-weight ratio and high impact resistance. Through injection or compression overmolding, composite tapes and multi- ply laminates are integrated into traditional thermoplastic molding processes to create locally-reinforced, molded components.